Roberto Caporali to Male
This is a "connection" page, showing publications Roberto Caporali has written about Male.
Connection Strength
0.169
-
A case report of monoarthritis in a COVID-19 patient and literature review: Simple actions for complex times. Medicine (Baltimore). 2021 Jun 11; 100(23):e26089.
Score: 0.013
-
Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy. Ann Rheum Dis. 2021 09; 80(9):1243-1245.
Score: 0.013
-
Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis. J Rheumatol. 2020 08 01; 47(8):1296.
Score: 0.012
-
What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. 2021 02; 80(2):e18.
Score: 0.012
-
Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial. Clin Rheumatol. 2019 Mar; 38(3):841-849.
Score: 0.011
-
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. Int J Rheum Dis. 2018 Feb; 21(2):422-430.
Score: 0.010
-
Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. Mod Rheumatol. 2018 May; 28(3):542-549.
Score: 0.010
-
Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. Clin Exp Rheumatol. 2017 Jul-Aug; 35(4):660-665.
Score: 0.010
-
Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. Clin Exp Rheumatol. 2017 Nov-Dec; 35(6):919-928.
Score: 0.010
-
Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies. Clin Exp Rheumatol. 2017 Nov-Dec; 35(6):899-906.
Score: 0.010
-
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol. 2017 Apr; 36(4):753-761.
Score: 0.009
-
Life-threatening onset of systemic vasculitis requiring intensive care unit admission: a case series. Clin Exp Rheumatol. 2015 Mar-Apr; 33(2 Suppl 89):S-126-31.
Score: 0.008
-
Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004 Oct 05; 141(7):493-500.
Score: 0.004
-
Telemedicine in rheumatology: a reliable approach beyond the pandemic. Rheumatology (Oxford). 2021 01 05; 60(1):366-370.
Score: 0.003
-
Cyclophosphamide plus granulocyte colony stimulating factor (G-CSF) is more effective than G-CSF alone in mobilizing hemopoietic progenitor cells in severe, refractory rheumatoid arthritis. Haematologica. 2001 Jan; 86(1):106-7.
Score: 0.003
-
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther. 2020 12 30; 22(1):290.
Score: 0.003
-
Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. J Autoimmun. 2021 01; 116:102545.
Score: 0.003
-
Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data? Arthritis Rheumatol. 2020 10; 72(10):1600-1606.
Score: 0.003
-
COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). Clin Exp Rheumatol. 2020 Jul-Aug; 38(4):748-753.
Score: 0.003
-
COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. Semin Arthritis Rheum. 2020 10; 50(5):1150-1157.
Score: 0.003
-
Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. Ann Rheum Dis. 2019 11; 78(11):1472-1479.
Score: 0.003
-
Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study. Clin Exp Rheumatol. 2019 May-Jun; 37(3):429-436.
Score: 0.003
-
Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018 03 01; 57(3):499-507.
Score: 0.003
-
Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35(5):804-809.
Score: 0.002
-
Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. J Rheumatol. 2016 05; 43(5):869-74.
Score: 0.002
-
Fetal programming and systemic sclerosis. Am J Obstet Gynecol. 2015 Dec; 213(6):839.e1-8.
Score: 0.002
-
Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci. 2006 Jun; 1069:315-21.
Score: 0.001
-
Impaired diastolic function in active rheumatoid arthritis. Relationship with disease duration. Clin Exp Rheumatol. 1999 Jul-Aug; 17(4):407-12.
Score: 0.001